BRIEF published on 07/30/2025 at 14:34, 8 months 2 days ago Medincell's Rising Revenue and Upcoming Submissions Schizophrenia Treatment Teva Partnership Medincell Revenue UZEDY Sales Olanzapine Submission
BRIEF published on 07/30/2025 at 14:34, 8 months 2 days ago Chiffre d'affaires croissant de Medincell et prochaines soumissions Traitement De La Schizophrénie Chiffre D'affaires De Medincell Ventes UZEDY Soumission D'olanzapine Partenariat Teva
PRESS RELEASE published on 07/30/2025 at 14:32, 8 months 2 days ago INFORMATIONS PRIVILÉGIÉES / AUTRES COMMUNIQUÉS Medincell accélère avec des prévisions de ventes 2025 relevées pour UZEDY® et confirmation de la demande de mise sur le marché américain pour l'Olanzapine LAI Schizophrénie Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 07/30/2025 at 14:29, 8 months 2 days ago INSIDE INFORMATION / OTHER NEWS RELEASES Medincell's partner Teva Pharmaceuticals raises 2025 revenue outlook for UZEDY® to $190–$200M and confirms Olanzapine LAI on track for submission in 2025 Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI Submission
BRIEF published on 07/30/2025 at 13:47, 8 months 2 days ago Medincell's UZEDY® and Olanzapine LAI Forecast Promising Financial Outcomes Schizophrenia Treatment Teva Pharmaceuticals Medincell Revenue Forecast UZEDY® Performance Olanzapine LAI Development
BRIEF published on 07/30/2025 at 13:47, 8 months 2 days ago Les prévisions de résultats financiers prometteurs pour les médicaments UZEDY® et Olanzapine LAI de Medincell Traitement De La Schizophrénie Teva Pharmaceuticals Prévisions De Revenus De Medincell Performances UZEDY® Développement De L'olanzapine LAI
PRESS RELEASE published on 07/30/2025 at 13:42, 8 months 2 days ago Informations privilégiées / Autres communiqués UZEDY® relève ses prévisions de ventes 2025 à 190–200 M$. Demande de mise sur le marché américain confirmée pour l'Olanzapine LAI en 2025. Medincell annonce les informations communiquées par Teva Pharmaceuticals Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY Ventes 2025
PRESS RELEASE published on 07/30/2025 at 13:42, 8 months 2 days ago Inside Information / Other news releases Medincell's partner Teva increases 2025 revenue outlook for UZEDY® to $190–$200M, plans olanzapine LAI submission. Company's innovative treatments aim to improve medicine accessibility Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
BRIEF published on 07/30/2025 at 11:43, 8 months 2 days ago Medincell Releases 2024-25 Universal Registration Document Shareholders Governance Financial Report CSR Medincell
BRIEF published on 07/30/2025 at 11:43, 8 months 2 days ago Medincell publie son document d'enregistrement universel 2024-25 Gouvernance Actionnaires RSE Rapport Financier Medincell
Published on 04/01/2026 at 18:15, 3 hours 50 minutes ago Loop Industries to Present at Gabelli Waste & Sustainability Symposium
Published on 04/01/2026 at 17:50, 4 hours 15 minutes ago Datavault AI Inc. (NASDAQ: DVLT) and Demora Foundation Execute Technology Integration Agreement to Power the K-Entertainment & K-Wave Global Platform
Published on 04/01/2026 at 17:00, 5 hours 5 minutes ago Stagwell Announces UNICEPTA UK and Hootsuite Strategic Partnership to Deliver Decision-Grade Media Intelligence Within the Talkwalker Platform
Published on 04/01/2026 at 16:00, 6 hours 5 minutes ago Norsemont Commences Trading on the OTCQX Market
Published on 04/01/2026 at 15:10, 6 hours 55 minutes ago A2Z Announces Audited Full-Year 2025 Financial Results
Published on 04/01/2026 at 19:25, 2 hours 40 minutes ago Annual General Meeting of HUBER+SUHNER AG: Shareholders endorse all proposals
Published on 04/01/2026 at 19:15, 2 hours 50 minutes ago Cango Inc. Completes US$65 Million Strategic Investment and Secures US$10 Million Convertible Note Financing to Strengthen Financial Position and Drive AI and Energy Expansion
Published on 04/01/2026 at 18:56, 3 hours 8 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/01/2026 at 19:16, 2 hours 48 minutes ago Mars 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Published on 04/01/2026 at 18:15, 3 hours 50 minutes ago Accor signs a memorandum of understanding on the sale of its stake in Essendi
Published on 04/01/2026 at 18:15, 3 hours 50 minutes ago Accor a signé un protocole d’accord pour la cession de sa participation dans Essendi
Published on 04/01/2026 at 18:02, 4 hours 3 minutes ago CP MOULINVEST : TRANSFERT DU CONTRAT DE LIQUIDITE AUPRES DE TPICAP
Published on 04/01/2026 at 18:00, 4 hours 5 minutes ago Closing of acquisition of Chaplin's World operating company
